Rades Dirk, Küchler Jan, Graumüller Lena, Abusamha Abdulkareem, Schild Steven E, Gliemroth Jan
Department of Radiation Oncology, University of Lubeck, 23562 Lubeck, Germany.
Department of Neurosurgery, University of Lubeck, 23562 Lubeck, Germany.
Cancers (Basel). 2022 Feb 28;14(5):1260. doi: 10.3390/cancers14051260.
In 2005, a randomized trial showed that addition of surgery to radiotherapy improved outcomes in patients with metastatic spinal cord compression (MSCC). Since then, only a few studies compared radiotherapy plus surgery to radiotherapy alone. We performed a retrospective matched-pair study including data from prospective cohorts treated after 2005. Seventy-nine patients receiving radiotherapy alone were matched to 79 patients assigned to surgery plus radiotherapy (propensity score method) for age, gender, performance score, tumor type, affected vertebrae, other bone or visceral metastases, interval tumor diagnosis to MSCC, time developing motor deficits, and ambulatory status. Improvement of motor function by ≥1 Frankel grade occurred more often after surgery plus radiotherapy (39.2% vs. 21.5%, = 0.015). No significant differences were found for post-treatment ambulatory rates (59.5% vs. 67.1%, = 0.32), local progression-free survival ( = 0.47), overall survival ( = 0.51), and freedom from in-field recurrence of MSCC (90.1% vs. 76.2% at 12 months, = 0.58). Ten patients (12.7%) died within 30 days following radiotherapy alone and 12 patients (15.2%) died within 30 days following surgery ( = 0.65); 36.7% of surgically treated patients did not complete radiotherapy as planned. Surgery led to significant early improvement of motor function and non-significantly better long-term control. Patients scheduled for surgery must be carefully selected considering potential benefits and risk of perioperative complications.
2005年,一项随机试验表明,对于转移性脊髓压迫(MSCC)患者,在放疗基础上加用手术可改善治疗效果。自那时起,仅有少数研究将放疗联合手术与单纯放疗进行了比较。我们开展了一项回顾性配对研究,纳入了2005年后接受治疗的前瞻性队列的数据。采用倾向评分法,将79例单纯接受放疗的患者与79例接受手术加放疗的患者,按照年龄、性别、体能状态评分、肿瘤类型、受累椎体、其他骨转移或内脏转移、肿瘤诊断至MSCC的间隔时间、出现运动功能障碍的时间以及步行状态进行配对。手术加放疗后运动功能改善≥1个Frankel分级的情况更为常见(39.2%对21.5%,P = 0.015)。治疗后的步行率(59.5%对67.1%,P = 0.32)、局部无进展生存期(P = 0.47)、总生存期(P = 0.51)以及MSCC野内无复发生存率(12个月时为90.1%对76.2%,P = 0.58)均未发现显著差异。单纯放疗后30天内有10例患者(12.7%)死亡,手术加放疗后30天内有12例患者(15.2%)死亡(P = 0.65);36.7%接受手术治疗的患者未按计划完成放疗。手术可显著早期改善运动功能,但长期控制效果无显著改善。对于计划接受手术的患者,必须在考虑围手术期并发症的潜在益处和风险的基础上进行仔细筛选。